Krsnaa Diagnostics Limited reported a consolidated net profit of ₹1,014.31 million for the financial year ended March 31, 2026, a 31% increase compared to the previous year. Revenue from operations for FY26 stood at ₹7,727.74 million, up from ₹7,171.60 million in FY25. The reported PAT includes a fair valuation gain of ₹222.41 million from the investment in Apulki Healthcare Private Limited. The board has recommended a final dividend of ₹2 per equity share, representing 40% of the face value, subject to shareholder approval.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹417.18 million on revenue from operations of ₹1,926.04 million, compared to a net profit of ₹206.78 million on revenue of ₹1,860.76 million in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹549 million versus ₹530 million in the same period last year, while the EBITDA margin came in at 29% compared to 29% year-on-year.

The following table summarises the key quarterly and full-year financial metrics:

Operational Highlights and Expansion

Operating cash flows strengthened significantly to ₹1,430.98 million in FY26 compared to ₹873.27 million in FY25. The retail diagnostics vertical, Krsnaa Retail Private Limited, delivered an 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states. A total of 51 centers and 1,167 collection centers were operationalized in FY25-26. The company projects that upon completion of its existing order book, it will have 200+ CT/MRI centres, cementing its position as one of Asia’s largest radiology players.

The Rajasthan project is expected to grow the network to 7 Reference Labs, 41 Mother Labs, 249 Satellite Labs & 5,000+ Collection Centres. Total assets as of March 31, 2026, stood at ₹18,237.16 million, compared to ₹12,815.95 million in the previous year.

Auditor and Regulatory Disclosures

The Statutory Auditors, MSKA & Associates LLP, issued an unmodified opinion on the audited standalone and consolidated financial results. The auditor's report included an emphasis of matter regarding assessment orders passed by the Income Tax Authorities for assessment years 2017-18 to 2023-24 under search assessment proceedings, resulting in a demand of ₹626.90 million. The company has filed appeals and deposited ₹102.77 million under protest, with management stating the demand is not tenable and not expected to have a material impact.

The board approved the re-appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27 to FY31, subject to shareholder approval.

Krsnaa Diagnostics Limited has made the audio recording of its post-earnings conference call available for stakeholders. The call, conducted to discuss financial results for the quarter and year ended March 31, 2026, was held on Tuesday, May 26, 2026, at 12:30 Hrs. (IST). The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The conference call featured a presentation by the company's management regarding the financial performance for the specified periods, followed by an interactive question-and-answer session. Key participants included Mr. Rajendra Mutha (Chairman & Whole-time Director), Mr. Yash Mutha (Managing Director), Mr. Mitesh Dave (Group CEO), Mr. Chandra Prakash Singh (Interim CFO), and Mr. Sujoy Bose (Head- Secretarial, Legal and Compliance).

Access to Recordings

The audio recording of the earnings call is now available on the official website of Krsnaa Diagnostics Limited. Stakeholders can access the recording via the specific link provided in the investors section.

The original access numbers for domestic and international participants are no longer required as the event has concluded. The company has confirmed that the recording link is now live for public access.